New drug helps in relieving Eczema's terrible itch
Sep 20, 2022
New Delhi, Sept 20 (ANI): Researchers involved in a new multi-site international phase III study led by Northwestern Medicine found that a new drug was highly effective in reducing the signs and symptoms of moderate-to-severe Eczema. This is the first study to treat moderate-to-severe Eczema in infants and children 6 months to 5 years of age with a biologic drug (monoclonal antibody) instead of immune-suppressing medications. More than half the children experienced at least a 75 per cent reduction in Eczema symptoms, highly significant reductions in itching, and improved sleep after a 16-week course of dupilumab, a drug that targets a crucial immunological system in allergens. This is the first massive, random, placebo-controlled trial of a monoclonal antibody for any skin condition, including Eczema, in kids as young as six months. The study, which covered 31 locations across Europe and North America, will be released in The Lancet on September 15.
